MCF-7Homo sapiens (Human)Cancer cell line
Also known as: MCF 7, MCF.7, MCF7, Michigan Cancer Foundation-7, ssMCF-7, ssMCF7, MCF7/WT, MCF7-CTRL, IBMF-7, MFC7 (Occasionally.), MFC-7 (Occasionally.)
Quick Overview
MCF-7 is a human breast cancer cell line used in cancer research and drug development.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0031 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Additional Information |
|
|---|---|
| Age | 69 |
| Age Category | Adult |
| Sex | Female |
| Race | caucasian |
| Subtype Features | ER+ |
Disease Information
| Disease | Invasive breast carcinoma of no special type |
|---|---|
| Lineage | Breast |
| Subtype | Invasive Breast Carcinoma |
| OncoTree Code | BRCA |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000019_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
| MutationSimple | GATA3 | p.Asp336Glyfs*17 (c.1006dupG) | Heterozygous | - | from parent cell line MCF-7 |
| MutationSimple | PIK3CA | p.Glu545Lys (c.1633G>A) | Heterozygous | - | from parent cell line MCF-7 |
| MutationNone reported | TP53 | - | - | - | PubMed=19787792 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.
Isola J.J.
Cancer Genet. Cytogenet. 126:1-7(2001).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.
NPJ Breast Cancer 8:12.1-12.12(2022).
The cancer SENESCopedia: a delineation of cancer cell senescence.";
Leite de Oliveira R., Wessels L.F.A., Bernards R.
Cell Rep. 36:109441.1-109441.22(2021).
Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010.
Samson J., Derlipanska M., Zaheed O., Dean K.
BMC Cancer 21:790.1-790.20(2021).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Mathematical modeling of tumor growth: the MCF-7 breast cancer cell line.
Wei H.-C.
Math. Biosci. Eng. 16:6512-6535(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.
Genome Res. 28:159-170(2018).
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Lakhani S.R.
Breast Cancer Res. Treat. 167:289-301(2018).
An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.
Lindbjerg Andersen C., Nielsen M.L., Olsen J.V.
Cell Syst. 4:587-599.e4(2017).
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
J. Proteome Res. 16:1391-1400(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
Mob. DNA 7:20.1-20.11(2016).
Insulin stimulated MCF7 breast cancer cells: proteome dataset.";
Sarvaiya H.A., Lazar I.M.
Data Brief 9:579-584(2016).
Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function.
Hartung T.
Sci. Rep. 6:28994-28994(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.
BMC Cancer 16:378.1-378.17(2016).
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Vandesompele J.
Sci. Data 3:160052-160052(2016).
Phosphoproteome and transcriptome of RA-responsive and RA-resistant breast cancer cell lines.
Carrier M., Joint M., Lutzing R., Page A., Rochette-Egly C.
PLoS ONE 11:E0157290-E0157290(2016).
Gene expression profiling and pathway analysis data in MCF-7 and MDA-MB-231 human breast cancer cell lines treated with dioscin.
Aumsuwan P., Khan S.I., Khan I.A., Walker L.A., Dasmahapatra A.K.
Data Brief 8:272-279(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Phosphoproteomic analysis identifies focal adhesion kinase 2 (FAK2) as a potential therapeutic target for tamoxifen resistance in breast cancer.
Stearns V., Gabrielson E.W., Sukumar S., Pandey A.
Mol. Cell. Proteomics 14:2887-2900(2015).
AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo.
Johnston S.R.D., Davies B.R., Dowsett M., Martin L.-A.
Mol. Cancer Ther. 14:2035-2048(2015).
Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors.
Cifani P., Kirik U., Waldemarson S., James P.
J. Proteome Res. 14:2819-2827(2015).
The story of MCF-7 breast cancer cell line: 40 years of experience in research.
Comsa S., Cimpean A.M., Raica M.
Anticancer Res. 35:3147-3154(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
The proteomic landscape of triple-negative breast cancer.";
Irie H.Y., Lee S.-I., Blau C.A., Villen J.
Cell Rep. 11:630-644(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
MCF-7 cells -- changing the course of breast cancer research and care for 45 years.
Lee A.V., Oesterreich S., Davidson N.E.
J. Natl. Cancer Inst. 107:djv073.1-djv073.4(2015).
Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development.
Magee A.I., Tate E.W.
Angew. Chem. Int. Ed. Engl. 54:5948-5951(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Research resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant.
Cavailles V., Korach K.S.
Mol. Endocrinol. 28:2072-2081(2014).
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
PLoS ONE 9:E92047-E92047(2014).
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.
Chernobrovkin A.L., Zubarev R.A.
PLoS ONE 9:E91433-E91433(2014).
Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis.
Ramirez-Clavijo S.R., Pasini B., Sapino A.
Mol. Cytogenet. 7:8.1-8.14(2014).
More than apples and oranges -- detecting cancer with a fruit fly's antenna.
Capuano R., Di Natale C.
Sci. Rep. 4:3576-3576(2014).
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Hirshfield K.M., Oltvai Z.N., Vazquez A.
Cancer Metab. 1:20.1-20.13(2013).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Breast Cancer Res. Treat. 142:237-255(2013).
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
McCormick F., Gray J.W.
Cancer Cell 24:450-465(2013).
Cell surface-specific N-glycan profiling in breast cancer.";
Shi S.-L., Chen C.-Y., Li Y.
PLoS ONE 8:E72704-E72704(2013).
Global proteome analysis of the NCI-60 cell line panel.";
Wilhelm M., Kuster B.
Cell Rep. 4:609-620(2013).
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer.
Linderholm B.K., Lehtio J.
Nat. Commun. 4:2175.1-2175.10(2013).
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
Cancer Res. 73:4372-4382(2013).
PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.
Beato M.
Cell Rep. 3:2021-2032(2013).
A novel approach for characterizing microsatellite instability in cancer cells.
Lu Y.-H., Soong T.D., Elemento O.
PLoS ONE 8:E63056-E63056(2013).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Dynamic DNA methylation across diverse human cell lines and tissues.
Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Genome Res. 23:555-567(2013).
Proteomic comparison of MCF-7 tumoursphere and monolayer cultures.";
Reynolds B.A., Gorman J.J., Lopez J.A.
PLoS ONE 7:E52692-E52692(2012).
Spanish human proteome project: dissection of chromosome 16.";
Blanco-Garcia F.J., Albar J.P., Corrales F.J.
J. Proteome Res. 12:112-122(2013).
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Science 336:1040-1044(2012).
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Rottapel R., Neel B.G., Moffat J.
Cancer Discov. 2:172-189(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Proteomic portrait of human breast cancer progression identifies novel prognostic markers.
Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M.
Cancer Res. 72:2428-2439(2012).
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
Yoon C.N., Chang Y.-T.
PLoS ONE 7:E32096-E32096(2012).
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
PLoS ONE 7:E31628-E31628(2012).
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Kong D.-X., Yamori T.
Bioorg. Med. Chem. 20:1947-1951(2012).
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
Reassessment of estrogen receptor expression in human breast cancer cell lines.
Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.
Anticancer Res. 31:521-527(2011).
Identification of fusion genes in breast cancer by paired-end RNA-sequencing.
Kallioniemi O.-P.
Genome Biol. 12:R6.1-R6.13(2011).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
Yamamoto S., Oka M., Hirano T., Sasaki K.
BMC Cancer 10:15.1-15.10(2010).
Systems-level modeling of cancer-fibroblast interaction.";
Finn S.P., Loda M., Mahmood U., Ramaswamy S.
PLoS ONE 4:E6888-E6888(2009).
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Breast Cancer Res. Treat. 121:53-64(2010).
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Pollack J.R.
PLoS ONE 4:E6146-E6146(2009).
DNA fingerprinting of the NCI-60 cell line panel.";
Chanock S.J., Weinstein J.N.
Mol. Cancer Ther. 8:713-724(2009).
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
Petersen O.W., Gray J.W., Bissell M.J.
Mol. Oncol. 1:84-96(2007).
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.
Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.
Clin. Exp. Metastasis 25:549-557(2008).
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
Ringner M., Hoglund M., Borg A.
Genes Chromosomes Cancer 46:543-558(2007).
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.
Biologicals 35:195-202(2007).
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
Cancer Cell 10:515-527(2006).
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mol. Cancer Ther. 5:2606-2612(2006).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Breast Cancer Res. Treat. 99:97-101(2006).
Comprehensive copy number profiles of breast cancer cell model genomes.
Shadeo A., Lam W.L.
Breast Cancer Res. 8:R9.1-R9.14(2006).
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
Cancer Res. 66:41-45(2006).
Molecular characterization of breast cancer cell lines by a low-density microarray.
Remacle J.
Int. J. Oncol. 27:881-892(2005).
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
Tomoda H., Yamori T., Tsuruo T.
J. Natl. Cancer Inst. 97:765-777(2005).
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Yamori T.
Mol. Cancer Ther. 4:399-412(2005).
HLA class I and II genotype of the NCI-60 cell lines.";
Morse H.C. 3rd, Stroncek D., Marincola F.M.
J. Transl. Med. 3:11.1-11.8(2005).
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Edwards P.A.W., Caldas C.
Carcinogenesis 26:923-930(2005).
Mutation of GATA3 in human breast tumors.";
Strausberg R.L., Chanock S.J., Borresen-Dale A.-L., Perou C.M.
Oncogene 23:7669-7678(2004).
Weightlessness acts on human breast cancer cell line MCF-7.";
Schoevaert-Brossault D.
Adv. Space Res. 32:1595-1603(2003).
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Edwards P.A.W., Chaffanet M.
Genes Chromosomes Cancer 37:333-345(2003).
Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
Dowsett M.
J. Biol. Chem. 278:30458-30468(2003).
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Santibanez-Koref M.F., Schlag P.M., Scherneck S.
Genes Chromosomes Cancer 37:29-35(2003).
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Birnbaum D., Chaffanet M.
Genes Chromosomes Cancer 35:204-218(2002).
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
Dodson A.R., Navabi H., Miller K.D., Balaton A.J.
Am. J. Clin. Pathol. 117:81-89(2002).
Short tandem repeat profiling provides an international reference standard for human cell lines.
Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
Cell lines from human breast.";
Leibovitz A.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).
Single cell transcriptome analysis upon MCF-7 breast cancer.";
Kuo H.-C., Chen C.-H., Chiu K.-P.
Genome Biol. 11 Suppl. 1:P8-P8(2010).
Breast cancer stem cells: tumourspheres and implications for therapy.";
Morrison B.J.
Thesis PhD (2010); Griffith University; Brisbane; Australia.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
Hart R.P., Furtado M.R.
J. Forensic Res. 2 Suppl. 2:5-5(2011).
The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture.
Lippman M.E., Bolan G., Huff K.
Cancer Res. 36:4595-4601(1976).
The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture.
Lippman M.E., Bolan G., Huff K.
Cancer Res. 36:4602-4609(1976).
The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.
Lippman M.E., Bolan G., Huff K.
Cancer Res. 36:4610-4618(1976).
Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture.
Wild M.J., Rudland P.S., Back D.J.
J. Steroid Biochem. Mol. Biol. 39:535-543(1991).
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
Induction of progesterone receptor in an estrogen, progesterone receptor-negative breast cancer cell line.
Heuson J.-C.
J. Steroid Biochem. 24:365-368(1986).
Replication of oncornavirus-like particle in human breast carcinoma cell line, MCF-7.
McGrath C.M., Grant P.M., Soule H.D., Glancy T., Rich M.A.
Nature 252:247-250(1974).
Estrogen receptor in a human cell line (MCF-7) from breast carcinoma.
Brooks S.C. Jr., Locke E.R., Soule H.D.
J. Biol. Chem. 248:6251-6253(1973).
A human cell line from a pleural effusion derived from a breast carcinoma.
Soule H.D., Vazquez J., Long A., Albert S., Brennan M.
J. Natl. Cancer Inst. 51:1409-1416(1973).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
Wright W.C., Daniels W.P., Fogh J.
J. Natl. Cancer Inst. 66:239-247(1981).
Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells.
Nawata H., Bronzert D.A., Lippman M.E.
J. Biol. Chem. 256:5016-5021(1981).
The E-screen assay: a comparison of different MCF7 cell stocks.";
Ruiz de Almodovar J.M., Pedraza V.
Environ. Health Perspect. 103:844-850(1995).
Effects of tamoxifen on potential doubling time of human breast cancer cell line determined by image cytometry of double fluorescent BrdU and DNA labeling.
Lagrange J.-L., Gioanni J., Caldani C.
Anticancer Res. 14:2025-2032(1994).
Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection.
Guan X.-Y., Meltzer P.S., Dalton W.S., Trent J.M.
Nat. Genet. 8:155-161(1994).
Insulin-like growth factor expression in human cancer cell lines.";
Grimley C., Battey J., Mulshine J.L., Cuttitta F.
J. Biol. Chem. 271:11477-11483(1996).
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Int. J. Cancer 67:816-820(1996).
MCF-7: the first hormone-responsive breast cancer cell line.";
Levenson A.S., Jordan V.C.
Cancer Res. 57:3071-3078(1997).
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Schellens J.H.M.
Cancer Chemother. Pharmacol. 41:307-316(1998).
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Oncogene 16:2865-2878(1998).
In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum.
Ohta H., Sakamoto H., Satoh K.
Cancer Lett. 134:111-118(1998).
Systematic variation in gene expression patterns in human cancer cell lines.
Botstein D., Brown P.O.
Nat. Genet. 24:227-235(2000).
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Isola J.J., Larsson C.
Genes Chromosomes Cancer 28:308-317(2000).
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Cancer Res. 60:4519-4525(2000).
Molecular cytogenetic analysis of breast cancer cell lines.";
Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Br. J. Cancer 83:1309-1317(2000).
Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?
Lilling G., Hacohen H., Nordenberg J., Livnat T., Rotter V., Sidi Y.
Cancer Lett. 161:27-34(2000).
Anecdotal Information
- Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)
- Have been flown in space on Foton-12 to study cytoskeleton architecture in microgravity (PubMed=11292682; PubMed=15002416)
- This is the first hormone-responsive breast cancer cell line to have been established